shine breast molecular
take home messag good breast molecular biggest
part sale healthi even acceler bad cyno
gyn either becom small matter pois rebound saw play
spade breast organ molecular ou also
strong revenu guidanc rais low end ep maintain
despit heavier fx pt
back knit
good result larg mirror recent pivot focu return
core breast molecular diagnost segment outperform
much bandwidth last year consum cynosur
disappoint goal stabil acquir segment rather
look sourc growth instead aesthet manag spend effort
core segment squar mid-singl digit growth top-line compani bit
lower organ bottom line consist faster top-line
aspir doubl digit result cash flow use tuck-in deal expand
reach area like breast biopsi ultim treatment faxitron focal
consist execut creat valu time stay buy pt
breast health surg highest growth new upgrad cycl take hold
global breast health growth surg cc cc last predominantli
jump us sale improv report report last acquisit
contribut faxitron focal ad growth ex-acquisit organ
growth improv global improv driven sever factor
seem sustain long tailwind ou convers digit inclus
recent releas offer acceler older holdout share gain
convers older newer system intellig clariti hd smart serv
ad growth among convers older unit net
new bit surpris consid penetr surpass mammo unit
us earli convers part driven invest
begin yield return natur turnov earli adopt base
market model nearli system place window least
half suffici age elig upgrad suggest driver alon sustain
breast growth mid-to-high singl digit remaind
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
buy predic return focu breast
molecular make revenu grow
well cynosur becom less focu drag
part busi remain stabl top-line growth
mid-sd includ acquisit ep growth high-sd
breast continu well new product
diagnost grow mid-singl digit driven molecular
panther test menu expans next year
thinprep novasur experi flat modest growth
next month
signific post cynosur
cynosur improv year unfold
geniu placement exceed expect
diagnost grow high-singl digit combo hpv
trich panther
cynosur return low doubl digit sooner expect
thinprep novasur experi mid-singl digit
growth next month
compani execut immedi accret follow
diagnost grow low-singl digit combo hpv trich
panther
continu eros cynosur busi follow
thinprep novasur experi low-singl digit
growth next month
compani unabl execut oper effici goal
pleas see import disclosur inform page report
financi summari market data
estim valuat
pleas see import disclosur inform page report
molecular continu show strength cc instal base panther
unit outsid us system year ago util
also go higher year ago util
us ou vastli differ ou market one approv
assay us menu fda test introduc sinc
start recent mycoplasma genitalium assay latest cytology/
perinat though note short-term weak much
smaller perinat segment overal busi remain flattish year
cyno continu fall gyn pois acceler
cyno yet find bottom segment take anoth leg competit
non-invas fat reduct market continu pain fda action women
health somewhat off-set growth skin product despit overal
aesthet declin mark new low busi less
focu continu explor new approach stabil ultim improv
busi includ matur sale forc new productsthough
segment offici card within gyn myosur segment
revenu grew hsd declin result basic flat perform versu
last year look ahead compani see improv sale execut paradox
new competitor catalyst reacceler stagnant segment
rais estim pt buy cyno
transit afterthought
rais prior reflect faster breast
growth revis prior off-set lower contribut cyno revis
prior heavier fx rais pt
prior reflect continu improv core breast molecular busi
tailwind suffici enough sustain growth balanc
year establish solid foundat upon build
pleas see import disclosur inform page report
pleas see import disclosur inform page report
